Dr MacDonald Michael Ross

Dr Michael Macdonald is a cardiologist at Mount Elizabeth Hospitals, Singapore.

His subspecialty is in heart failure, preventative cardiology and cardiac imaging. He is experienced in managing complex heart failure cases and inherited cardiomyopathies, including those requiring device and cardiac transplantation.

He has a special interest in the management of complex hypertension, hyperlipidemia and diabetes, to halt coronary artery disease, prevent heart attack and stroke, and increase longevity. He is also a certified obesity physician and has a particular interest in the weight management of those with heart disease.

Prior to joining private practice, Dr Macdonald was a cardiologist at Changi General Hospital in Singapore from 2015 to 2019, where he was part of the development of its heart failure and cardiac imaging services. He was the director of cardiac MRI at the department of cardiology, and the director of heart failure assistance at Changi General Hospital.

He was also a former cardiologist at UK's Greater Glasgow and Clyde at the general cardiology and inherited cardiac conditions service.

He received his UK training certificate in 2013 and was appointed consultant cardiologist at Western Infirmary, Glasgow, UK. He undertook a 3-year fellowship at the Scottish National Advanced Heart Failure and Transplant Unit at the Golden Jubilee National Hospital, UK, where he also completed a second research degree on the relationship between diabetes and heart failure. He then underwent a fellowship in cardiac MRI at the Royal Brompton Hospital, London.

Dr Macdonald was elected a member of the Royal College of Physicians in 2004 and a fellow of the European Society of Cardiology in 2010.

In 2019, he was appointed as an adjunct associate professor at Duke-NUS Medical School. He has been practising medicine for more than 20 years.

He has a track record in basic, epidemiological and clinical research, and his primary research interest is in the relationship between diabetes and heart failure. He has published extensively in leading journals and is a reviewer for journals including The Lancet and the European Heart Journal, and regularly sits on committees for international large-scale randomised controlled trials.

He was a keynote speaker at the Japanese Circulation Society on the treatment of cardiovascular disease in diabetes. He was also on the European Society of Cardiology’s workshop committee and chair of the endpoint committee of the ASIAN-HF (heart failure) study.